Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GMAB) Non-Current Deffered Revenue: 2020-2021

  • Genmab A's Non-Current Deffered Revenue rose 15.01% to $57.83 in Q2 2021 from the same period last year, while for Jun 2021 it was $57.83, marking a year-over-year increase of 15.01%. This contributed to the annual value of $56.6 million for FY2020, which is N/A change from last year.
  • Genmab A's Non-Current Deffered Revenue amounted to $57.83 in Q2 2021, which was down 100.00% from $56.6 million recorded in Q4 2020.
  • Genmab A's Non-Current Deffered Revenue's 5-year high stood at $56.6 million during Q4 2020, with a 5-year trough of $50.28 in Q2 2020.
  • Moreover, its 2-year median value for Non-Current Deffered Revenue was $57.83 (2021), whereas its average is $18.9 million.
  • Data for Genmab A's Non-Current Deffered Revenue shows a peak YoY climbed of 15.01% (in 2021) over the last 5 years.
  • Genmab A's Non-Current Deffered Revenue (Quarterly) stood at $56.6 million in 2020, then increased by 15.01% to $57.83 in 2021.
  • Its last three reported values are $57.83 in Q2 2021, $56.6 million for Q4 2020, and $50.28 during Q2 2020.